8.47
Tango Therapeutics Inc stock is traded at $8.47, with a volume of 3.41M.
It is up +18.63% in the last 24 hours and up +29.71% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$7.14
Open:
$7.25
24h Volume:
3.41M
Relative Volume:
1.72
Market Cap:
$942.37M
Revenue:
$24.30M
Net Income/Loss:
$-145.57M
P/E Ratio:
-6.3684
EPS:
-1.33
Net Cash Flow:
$-149.17M
1W Performance:
+11.74%
1M Performance:
+29.71%
6M Performance:
+500.71%
1Y Performance:
+23.47%
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TNGX
Tango Therapeutics Inc
|
8.47 | 794.40M | 24.30M | -145.57M | -149.17M | -1.33 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-19-25 | Initiated | Piper Sandler | Overweight |
Jul-17-24 | Initiated | Jefferies | Buy |
Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
Feb-12-24 | Initiated | Piper Sandler | Overweight |
Dec-08-23 | Initiated | B. Riley Securities | Buy |
Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Multi asset correlation models including Tango Therapeutics Inc.2025 Price Action Summary & Risk Adjusted Buy/Sell Alerts - newser.com
What earnings revisions data tells us about Tango Therapeutics Inc.Portfolio Performance Report & Free Accurate Trade Setup Notifications - newser.com
Best data tools to analyze Tango Therapeutics Inc. stock2025 Price Momentum & Low Drawdown Momentum Trade Ideas - newser.com
Detecting price anomalies in Tango Therapeutics Inc. with AIJuly 2025 PreEarnings & AI Enhanced Trade Execution Alerts - newser.com
Developing predictive dashboards with Tango Therapeutics Inc. dataWeekly Stock Recap & Real-Time Volume Analysis - newser.com
How to build a dashboard for Tango Therapeutics Inc. stockJuly 2025 Outlook & Consistent Profit Alerts - newser.com
Is Tango Therapeutics Inc. stock entering bullish territoryJuly 2025 Chart Watch & Risk Adjusted Buy and Sell Alerts - newser.com
Tango Therapeutics Inc. stock trendline breakdownIPO Watch & Reliable Entry Point Alerts - newser.com
Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock? - MSN
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $10.50 Average PT from Analysts - Defense World
Will Tango Therapeutics Inc. benefit from macro trendsChart Signals & Reliable Price Action Trade Plans - newser.com
Is a relief rally coming for Tango Therapeutics Inc. holders2025 Market Overview & Fast Moving Trade Plans - newser.com
Market reaction to Tango Therapeutics Inc.’s recent newsBull Run & Free Expert Approved Momentum Trade Ideas - newser.com
Real time alert setup for Tango Therapeutics Inc. performance2025 Major Catalysts & Safe Capital Growth Plans - newser.com
Tango Therapeutics' (TNGX) Sell (E+) Rating Reaffirmed at Weiss Ratings - MarketBeat
Historical volatility pattern of Tango Therapeutics Inc. visualizedMarket Activity Summary & Fast Moving Market Watchlists - newser.com
Real time social sentiment graph for Tango Therapeutics Inc.Earnings Growth Summary & Daily Entry Point Trade Alerts - newser.com
Tango To Present At The 2025 SITC Annual Meeting — Will New Insights Make Waves? - RTTNews
Regression analysis insights on Tango Therapeutics Inc. performanceTrade Ideas & Daily Oversold Bounce Ideas - newser.com
Is Tango Therapeutics Inc. building a consolidation base2025 Major Catalysts & Breakout Confirmation Trade Signals - newser.com
Tango Therapeutics’ SWOT analysis: biotech stock’s promise amid clinical trials By Investing.com - Investing.com South Africa
Tango Therapeutics’ SWOT analysis: biotech stock’s promise amid clinical trials - Investing.com UK
Tango Therapeutics to Present First Clinical Data from - GlobeNewswire
First clinical data: TNG260 — Tango Therapeutics presents Phase 1/2 results at SITC Nov 7 - Stock Titan
Building trade automation scripts for Tango Therapeutics Inc.Weekly Stock Analysis & Daily Growth Stock Investment Tips - newser.com
Published on: 2025-10-05 03:22:51 - newser.com
Piper Sandler Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $11 - 富途牛牛
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu - Barchart.com
Multi factor analysis applied to Tango Therapeutics Inc.Bull Run & Fast Momentum Entry Tips - newser.com
How to use Fibonacci retracement on Tango Therapeutics Inc.Weekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Tango Therapeutics Hits New 52-Week High of $8.79, Marking Major Milestone - Markets Mojo
Healthcare veteran David Wilkinson to join Tango as chief financial officer - MarketScreener
Tango Therapeutics CEO Barbara Weber sells $57,710 in stock - MSN
Published on: 2025-09-30 04:30:06 - newser.com
Published on: 2025-09-30 03:51:20 - newser.com
Major Shareholder Sells Off Tango Therapeutics Stock in Multi-Million Dollar Deal! - TipRanks
Tango Therapeutics (NASDAQ:TNGX) Major Shareholder Rock Ventures Iv L.P. Third Sells 500,000 Shares - MarketBeat
Tango Therapeutics, Inc. $TNGX Position Reduced by Goldman Sachs Group Inc. - Defense World
Tango Therapeutics Hits New 52-Week High at $8.56 - Markets Mojo
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):